Professor of Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, and Attending Physician, Pediatric Emergency Medicine, Nemours/Alfred I duPont ...
New RSV shots and monoclonals cut infant hospitalizations up to 85%, with strong real‑world safety—learn what efficacy vs effectiveness really means. This episode provides a clear-eyed analysis of ...
A Nemours program trained pediatric residents to conduct autism evaluations, improving confidence and helping families access care sooner. Long waits for autism evaluations continue to delay diagnosis ...
A titanium-based lithium coin-cell battery reduced visible esophageal tissue injury compared with traditional batteries in a porcine model. The protective battery still generated alkaline hydroxide, ...
An expert reviews the pediatric IBS-C label expansion for linaclotide, discusses how it addresses historical evidence gaps, and outlines practical considerations for patient selection, counseling, and ...
The FDA approved the first generic version of rifapentine tablets, previously marketed as Priftin. Rifapentine is indicated for active pulmonary tuberculosis in patients aged 12 years and older and ...
The FDA's Warning Letter identifies the SNOO X-Small and X-Large sleep sacks as unauthorized modifications to an FDA-cleared device; clinicians should caution families to discontinue use of these ...
Any infant who consumed Nara Organics Whole Milk Organic Powdered Infant Formula and presents with constipation, poor feeding, hypotonia, loss of head control, or facial weakness should be evaluated ...
The US Food and Drug Administration (FDA) has cleared Dexcom's Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor (CGM) for children, expanding the integrated CGM ...
The FDA approved lebrikizumab-lbkz (EBGLYSS) for a maintenance dosing regimen of 250 mg every 8 weeks in adults and adolescents ≥12 years and ≥40 kg with moderate-to-severe atopic dermatitis, allowing ...
The FDA has accepted for review Takeda's sBLA for IV vedolizumab in patients ages 2 and older with moderately to severely active UC or Crohn's disease; a regulatory decision is expected by Q1 2027.
The FDA approved tocilizumab-bavi (TOFIDENCE) for CAR T-cell–induced severe or life-threatening CRS and hospitalized COVID-19 in adults and children aged ≥2 years, completing label alignment with all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results